China-based biotech Minghui Pharmaceutical Inc. has reported that the first dosing has been completed in two Phase I studies assessing the company’s antibody drug conjugate (ADC) candidate drugs, MHB036C and MHB088C. Both candidates are developed on Minghui’s proprietary SuperTopoi platform, with MHB036C targeting TROP2 and MHB088C targeting B7-H3.
SuperTopoi Platform and Payload Design
Minghui’s SuperTopoi platform incorporates a highly potent topoisomerase (TOPO) 1 inhibitor linked through a cleavable linker, representing a novel payload that potentially differentiates its drug candidates from competitors in the market. This design is said to significantly enhance the therapeutic potency of these ADCs, particularly against cancer cells with moderate or low tumor-associated antigen expression.
Preclinical Efficacy and Phase I Study Goals
In preclinical tests, MHB036C and MHB088C demonstrated 3 to 10 times more efficacy in terms of tumor cell toxicity compared to peer drugs. The Phase I studies will first assess the safety of these ADCs and then aim to set the recommended Phase II dose. Additionally, the studies will gauge initial pharmacokinetics (PK) and efficacy, providing valuable data on the drugs’ behavior and potential effectiveness in vivo.-Fineline Info & Tech
